Oxaliplatin
Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of gastrointestinal malignancies, especially colorectal and gastric cancers.
Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of gastrointestinal malignancies, especially colorectal and gastric cancers. It is a third-generation platinum compound and is structurally distinct from cisplatin and carboplatin, with a broader clinical role in combination regimens such as fluorouracil/leucovorin-based therapy, capecitabine plus oxaliplatin (CapeOX or XELOX), and oxaliplatin-containing multi-drug protocols.
Biologically, oxaliplatin exerts antitumor activity through platinum-DNA adduct formation, leading to DNA damage, replication stress, and cell death. In recent research, it has also been studied in relation to resistance mechanisms, immunogenic cell death, ferroptosis, autophagy, and tumor microenvironment remodeling. These studies reflect its continuing importance not only as a standard cytotoxic drug, but also as a reference compound in investigations of combination therapy, drug delivery systems, and mechanisms of chemotherapy resistance.
Where the papers sit
19 papers from the last 6 months study oxaliplatin directly · updated from PubMed 11 Oct 2026
Study type 3 clinical trials · 3 observational · 1 human data · 10 preclinical · 2 unclassified
Themes one subject · 1 new direction
Those 19 are all about one subject.
-
Platinum Chemotherapy in Cancer
Platinum chemotherapy research spans gastrointestinal, ovarian, pancreatic and lymphoma treatment, with emphasis on improving efficacy and tolerability. Clinical work evaluates SOX, cytoreductive surgery with HIPEC, and glofitamab-based combinations, while genomic profiling seeks better treatment selection. Preclinical studies target resistance through NRF2, DNA-damage responses and ferroptosis, and explore extracellular-vesicle or nanoparticle delivery. The field remains broad, without one strategy established across cancer types.
Oxaliplatin is documented as a potential sexual-exposure hazard during chemotherapy
The subject of the rectal-cancer case report is oxaliplatin detected in vaginal secretions during FOLFOX treatment, rather than oxaliplatin as an antitumor agent, resistance determinant, delivery cargo, or treatment component. Urine contained detectable oxaliplatin for up to three days after chemotherapy, while polysorb vaginal swabs detected it on day one at approximately the limit of detection, with an estimated maximum of 2.5 ng per swab. This extends oxaliplatin research into survivorship safety and sexual-exposure assessment, creating a practical basis for counseling and exposure-risk evaluation during treatment 42855709Oct.
Papers
The 19 papers from the last 6 months that study oxaliplatin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Platinum Chemotherapy in Cancer (19)
- Assessing sexual exposure to oxaliplatin in vaginal secretions during FOLFOX chemotherapy: a case report. Journal of medical case reports · 9 Oct 2026 PMID 42855709
- Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy. Drug delivery · 22 Sept 2026 PMID 42771518
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience. Radiology and oncology · 7 Sept 2026 PMID 42704034
- An immune-activated co-culture model of patient-derived gastric cancer organoids and peripheral blood mononuclear cells for personalized chemotherapy screening. Acta biomaterialia · 30 Aug 2026 PMID 42669342
- Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600610
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
- A nucleolar stress gene signature enables quantitative scoring across multi-omics contexts. Communications biology · 29 Jun 2026 PMID 42373768
- Biomimetic adhesive hydrogel microcarriers for gas therapy and chemotherapy of gastric cancer. Acta biomaterialia · 12 Jun 2026 PMID 42285389
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
- Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. ACS nano · 1 Jun 2026 PMID 42225301
- RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 May 2026 PMID 42217457
- Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
- Artesunate overcomes oxaliplatin resistance in colorectal cancer by inducing ferroptosis through inhibition of the CDK5/Nrf2/GPX4 pathway. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42178429
- Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report. Cancer chemotherapy and pharmacology · 13 May 2026 PMID 42126571
- The role of Ca2+/calmodulin-dependent protein kinase II in oxaliplatin resistance of colorectal cancer: In vitro and in vivo studies. Gene · 5 May 2026 PMID 42086109
- Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 22 Apr 2026 PMID 42018958
- Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. Cancer science · 16 Apr 2026 PMID 41989931
By study type
Clinical trials (3)
- Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600610
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
- Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 22 Apr 2026 PMID 42018958
Observational studies and case reports (3)
- Assessing sexual exposure to oxaliplatin in vaginal secretions during FOLFOX chemotherapy: a case report. Journal of medical case reports · 9 Oct 2026 PMID 42855709
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience. Radiology and oncology · 7 Sept 2026 PMID 42704034
- Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report. Cancer chemotherapy and pharmacology · 13 May 2026 PMID 42126571
Human data, design not indexed (1)
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
Preclinical: animal, cell and lab studies (10)
- Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy. Drug delivery · 22 Sept 2026 PMID 42771518
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- An immune-activated co-culture model of patient-derived gastric cancer organoids and peripheral blood mononuclear cells for personalized chemotherapy screening. Acta biomaterialia · 30 Aug 2026 PMID 42669342
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Biomimetic adhesive hydrogel microcarriers for gas therapy and chemotherapy of gastric cancer. Acta biomaterialia · 12 Jun 2026 PMID 42285389
- RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 May 2026 PMID 42217457
- Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
- Artesunate overcomes oxaliplatin resistance in colorectal cancer by inducing ferroptosis through inhibition of the CDK5/Nrf2/GPX4 pathway. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42178429
- The role of Ca2+/calmodulin-dependent protein kinase II in oxaliplatin resistance of colorectal cancer: In vitro and in vivo studies. Gene · 5 May 2026 PMID 42086109
- Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. Cancer science · 16 Apr 2026 PMID 41989931
Unclassified: not yet indexed with MeSH (2)
- A nucleolar stress gene signature enables quantitative scoring across multi-omics contexts. Communications biology · 29 Jun 2026 PMID 42373768
- Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. ACS nano · 1 Jun 2026 PMID 42225301
Written from 19 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-24 by GPT. Drafted by language models from published abstracts; not medical advice.